May be administered by registered competent doctor or nurse/midwife
Paricalcitol 5 micrograms in 1mL (Pinewood)
Zemplar 5microgram in 1mL - no longer marketed, but stock remains in UCH, Galway
Already in solution
Draw up using a 5 micron filter needle
Not required
Depends on baseline parathyroid hormone (PTH) levels and units used to express PTH levels (see table below):
Initial dose
PTH measured in pmol/l (see below for dose) | PTH measured in pg/ml (see below for dose) |
---|---|
Initial dose (micrograms)= baseline intact PTH (pmol/l) / 8 | Initial dose (micrograms) = baseline intact PTH (pg/ml) / 80 |
Use in NON-haemodialysis patients is outside the product license. Therefore dosing recommendations may not be appropriate. In such circumstances laboratory monitoring is critical.
Titration dose: suggested guidelines based on intact PTH (iPTH) below
Dosage adjustments should be made every 2 to 4 weeks | |
---|---|
iPTH level relative to baseline | Paricalcitol dose adjustment |
Same or increased | Increase by 2 to 4 micrograms |
Decreased by LESS than 30% | |
Decreased by 30 to 60% | Maintain |
Decreased by GREATER than 60% | Decrease by 2 to 4 micrograms |
iPTH LESS than 15.9 pmol/l (150pg/ml) |
In patients with clinically significant hypercalcaemia, consider cessation or a reduction in dose of the paricalcitol (see SPC for further details).
Suggested monitoring during maintenance phase (below)
Parameter | Monitoring frequency |
---|---|
Calcium and phosphate | At least monthly |
Serum intact PTH (iPTH) | Three monthly |
During the titration phase monitoring may be required more frequently
No particular storage requirements
Pinewood brand SPC Jan 2020
1: Injectable Drugs guide, downloaded from Medicinescomplete 24th Jan 2023
Synthetic, biologically active vitamin D analogue of calcitriol